Últimas noticias sobre Novo Nordisk (NYSE:NVO) Bolsa

Novo Nordisk

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

News

Trading Ideas

Elon Musk respalda Mounjaro en la batalla contra Ozempic. ¿Qué implican sus opiniones para la industria de pérdida de peso?

Medicamentos para adelgazar: La batalla entre Mounjaro y Ozempic con Elon Musk como protagonista

AADI

APTO

CADL

CARA

HUMA

MESO

MOBX

MTEM

NVNI

OCEA

PRFX

QUBT

ZCAR

FedEx sube un 8,7% con resultados sólidos y una nueva estrategia. Descubre otras acciones destacadas en premercado hoy.

Las acciones de FedEx (FDX) suben alrededor de un 9%; 20 acciones que se mueven en premercado

Biotech

Large Cap

Health Care

Movers

General

Novo Nordisk revela datos sobre Amycretina, un nuevo medicamento para pérdida de peso, que mostró una baja del 13,1% en peso en 12 semanas.

Novo Nordisk presenta resultados de su nuevo fármaco para pérdida de peso, Amycretina

Novo Nordisk AS

Precidian ETFs Trust Novo Nordisk A/S B Shares ADRhedged

Novo Resources Corp Warrants (27/08/2023)

NOVO INTEGRATED SCIENCES by Novo Integrated Sciences, Inc.

Novo Integrated Sciences Inc

Tidal Trust II Defiance Daily Target 2X Long NVO ETF

On Monday, AbbVie&nbsp;Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) and Gubra A/S announced a license agreement to develop GUB014295, a long-acting amylin analog for obesity. GUB014295 is currently in a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44069717/abbvie-and-gubra-announce-license-agreement-to-develop-an-amylin-analog-for-the-treatment-of-obesi" rel="noreferrer noopener">Phase 1 clinical trial</a>.
&#8220;Our partnership with Gubra marks our entry into the obesity field, offering a compelling opportunity based on the potential to address patient needs while also fostering long-term growth for our company,&#8221; said&nbsp;Robert Michael, CEO of AbbVie.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/01/43403416/is-big-pharma-about-to-win-goldman-sachs-weighs-in-on-340b-and-medicaid-shifts" rel="noreferrer noopener">Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts</a>
A potential long-acting amylin analog, GUB014295 is an agonist that specifically activates amylin and calcitonin receptors.
Amylin, a satiety hormone, has been identified as a potential therapeutic target for obesity, given its role in activating signals to the brain that result in appetite suppression and the reduction of food intake while also acting as an inhibitory signal to delay gastric emptying.&nbsp;
Under the terms of the agreement, AbbVie will lead the development and commercialization activities of GUB014295 globally.
Gubra will receive&nbsp;$350 million&nbsp;in total upfront payment and be eligible to receive up to&nbsp;$1.875 billion&nbsp;in development, commercial and sales milestone payments with tiered royalties on global net sales.
William Blair analyst Matt Phipps writes, &#8220;We believe this transaction highlights a growing interest in amylin agonists (and particularly dual amylin/calcitonin receptor agonists, or DACRAs) as a next wave of obesity assets, particularly for companies looking to break into the field despite being well behind GLP-1 leaders Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>).&#8221;
The analyst highlights a key question is whether AbbVie will develop GUB014295 as a standalone treatment, offering a milder weight loss option for those who cannot tolerate or do not respond to GLP-1/GIP agonists.
Alternatively, the company may combine it with GLP-1/GIP drugs like Novo Nordisk's CagriSema for greater weight loss. Investors are also interested in whether AbbVie plans to expand further in the obesity market through new business deals.
Price Action: ABBV stock is up 0.84% at $210.78 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44080418/trimble-and-stmicroelectronics-launch-precision-positioning-tech-for-iot-applications" target="_blank" rel="noreferrer noopener">Trimble, STMicroelectronics Launch Precision Positioning Tech For IoT Applications</a></li>
</ul>
Photo via Shutterstock.

Analyst Color

Analyst Ratings

ABBV

GUBRF

AbbVie Becomes Another Big Pharma To Enter Obesity Treatment Race

Stocks in the United States are off to a choppy but positive start to the year, but the biggest story in markets so far in 2025 has been strength out of Europe.
Stock indices in England, France, and Germany have made new all-time highs in 2025, outpacing the modest gains from US stocks. The Vanguard FTSE Europe ETF is up more than 8% over the last three months, while the SPDR S&amp;P 500 ETF has traded flat.
Here&#8217;s how to get in on this rally.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="415" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26181506/image7-1024x415.png" alt="" class="wp-image-800481" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26181506/image7-1024x415.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26181506/image7-300x122.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26181506/image7-768x311.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26181506/image7.png 1318w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
The Stoxx 600 index, which covers markets across the bloc, made several new all-time highs in February, led by a surge from the defense sector. Is this finally the year that European stocks beat their American counterparts? With the United States threatening to pull back from Europe, these tailwinds may have more room to run, especially if the EU follows through on defense spending expansion.
Today we'll look at six European stocks that could continue outperforming in 2025. Some of these companies are available to US investors through American Depositary Receipts (ADRs) or on over-the-counter (OTC) exchanges, so be sure to understand how these assets and markets function before putting any capital to work.
<h2 class="wp-block-heading">Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)</h2>
Danish healthcare giant Novo Nordisk is responsible for Wegovy and Ozempic, two of the prescription GLP-1 medications taking the world by storm. Both are different forms of semaglutide, as Wegovy is FDA-approved for weight loss while Ozempic is only approved for Type 2 diabetes. Demand for these drugs has been so strong that shortages have been common, but the FDA recently announced that Wegovy and Ozempic are no longer on their shortage list.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="416" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26181516/image1-1024x416.png" alt="" class="wp-image-800482" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26181516/image1-1024x416.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26181516/image1-300x122.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26181516/image1-768x312.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26181516/image1.png 1316w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Novo Nordisk suffered a lost year in 2024 during the shortage, losing ground to Eli Lilly's Mounjaro and Zepbound. However, the company is still the top player in the GLP-1 space and posted solid revenue (8.1%) and earnings (9.6%) growth in the most recent report for Q4 2024.
The company's margins are also the envy of European drug makers: 34.8% gross, far outpacing EU competitors AstraZeneca (13%) and Roche (17.5%). NVO also sits on a formidable $9.8 billion cash pile. NVO shares have been choppy since the start of 2025, but the company issued strong guidance and is well-positioned to rebound after a rough 2024.
<h2 class="wp-block-heading">Unilever PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UL#NYSE">UL</a>)</h2>
Unilever is a global consumer and household products company that markets itself under popular brands such as Ben and Jerry's, Axe, Dove, Breyers, Vaseline, and many more. The firm has offices in over 80 countries, but its headquarters has been in London for more than 100 years.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="417" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26181610/image6-1024x417.png" alt="" class="wp-image-800488" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26181610/image6-1024x417.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26181610/image6-300x122.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26181610/image6-768x313.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26181610/image6.png 1310w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Uncertainty is beginning to weigh on investors as US consumer discretionary stocks have been tumbling for most of February while consumer staples surge higher. There's some evidence that businesses and consumers have been pulling forward demand on tariff threats, which could further boost the staples sector if big-ticket items have been already purchased and consumers focus on necessities over luxuries.
UL has a strong cash position and healthy margins to take advantage of this trend; it's also cheaper in terms of forward price-to-earnings and price-to-sales rates than American counterparts like Proctor and Gamble, Kimberly-Clark, and Colgate-Palmolive.
<h2 class="wp-block-heading">Airbus SE (OTC:<a class="ticker" href="https://www.benzinga.com/stock/EADSY#OTC">EADSY</a>)</h2>
Now, on to the defense contractors, who have been leading the European rally due to expectations that EU governments will ramp up defense spending to counter the growing influence of China and Russia in the East. Companies like Rheinmetall AG have stolen the headlines with substantial early 2025 gains, but Airbus might be the best buy of the group going forward.Now, on to the defense contractors, who have been leading the European rally due to expectations that EU governments will ramp up defense spending to counter the growing influence of China and Russia in the East. Companies like Rheinmetall AG have stolen the headlines with substantial early 2025 gains, but Airbus might be the best buy of the group going forward.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="417" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26181602/image5-1024x417.png" alt="" class="wp-image-800487" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26181602/image5-1024x417.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26181602/image5-300x122.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26181602/image5-768x313.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26181602/image5.png 1310w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Airbus is under the European Aeronautic Defense and Space Co. (EADS) umbrella and has a market cap of $139 billion, nearly $33 billion more than its closest competitor, Safran SA. Airbus has a cheaper valuation than Safran or Rheinmetall and a healthier free cash flow pile ($3.9 billion). Airbus might not be lagging in the European defense sector for much longer.
<h2 class="wp-block-heading">BNP Paribas SA (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BNPQY#OTC">BNPQY</a>)</h2>
BNP Paribas is a French bank and component of the CAC40, the country&#8217;s primary stock index. With a market value of over $80 billion, it is double the size of other European banking competitors like Societe Generale and Deutsche Bank.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="417" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26181526/image2-1024x417.png" alt="" class="wp-image-800483" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26181526/image2-1024x417.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26181526/image2-300x122.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26181526/image2-768x313.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26181526/image2.png 1310w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
BNP Paribas is attractive for several reasons, none more so than the 7.03 forward P/E ratio and 1.22 P/S ratio. Many European banks have extremely affordable valuations, but BNP offers the security of a large-cap with the upside of a smaller company. Plus, the 5% dividend yield is a nice bonus for investors.
<h2 class="wp-block-heading">Hermes International ADR (OTC:<a class="ticker" href="https://www.benzinga.com/stock/HESAY#OTC">HESAY</a>)</h2>
If one luxury brand can survive a consumer slowdown, it might be Hermes International, the high-end French brand with a nearly $300 billion market cap and some of the most desirable handbags in the world. In addition to handbags, Hermes sells clothing for men and women, equestrian products like saddles and bridles, jewelry, perfumes, watches, and tableware.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="417" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26181535/image3-1024x417.png" alt="" class="wp-image-800484" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26181535/image3-1024x417.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26181535/image3-300x122.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26181535/image3-768x313.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26181535/image3.png 1310w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Hermes has a pricey valuation compared to European competitors like Louis Vuitton, Prada, and Burberry, but the free cash pile is large ($5.38 billion) and the 30% profit margin dwarfs them all. The stock is up more than 38% in the last three months alone, but the fundamentals are strong, and the stock is comfortably above its 50-day and 200-day moving averages with a Relative Strength Index (RSI) reading of 55.
<h2 class="wp-block-heading">ABB Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ABBNY#OTC">ABBNY</a>)</h2>
ABB Ltd. is a multinational robotics and automation solutions company incorporated in Switzerland and Sweden. The company has several divisions of interest to the defense and aeronautics sector, such as Electrification, Process Automation, and Robotics and Discrete Automation. The stock has a market cap of just under $102 billion and pays a 1.7% dividend yield.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="414" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26181543/image4-1024x414.png" alt="" class="wp-image-800485" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26181543/image4-1024x414.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26181543/image4-300x121.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26181543/image4-768x311.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/26181543/image4.png 1305w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
ABB Ltd. currently sits on a $4.2 billion cash pile and a forward P/E ratio of 22.6, with a profit margin of 11.9%. The stock has been range-bound since spring 2024 and recently dipped down to its 50-day moving average. If the 50-day proves to be a support level, the next leg higher for ABBNY shares could be right around the corner.

Opinion

ABBNY

BNPQY

European Aeronautic Defence And Space Unsponsored

EADSY

HESAY

6 Stocks to Buy as European Markets Soar

Last week, the Food and Drug Administration (FDA) said Novo Nordisk A/' (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) semaglutide products, including Wegovy and Ozempic, are no longer in shortage.
Semaglutide injection products were <a target="_blank" href="https://www.fda.gov/media/185526/download?attachment" rel="noreferrer noopener">first</a> added to the FDA's drug shortage list for Wegovy in March 2022 and Ozempic in August 2022.
A lawsuit filed by the compounding groups Outsourcing Facilities Association (OFA) and North American Custom Laboratories, doing business as FarmaKeio Superior Custom Compounding, challenges the FDA's decision to remove semaglutide from the drug shortage list.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43812904/novo-nordisk-sues-singapore-based-kbp-biosciences-over-alleged-data-misrepresentation-in-13-billion-hypertension-drug-deal-seeks-over-800-million-in-damages" rel="noreferrer noopener">Novo Nordisk Sues Singapore-Based KBP Biosciences Over Alleged Data Misrepresentation In $1.3 Billion Hypertension Drug Deal, Seeks Damages</a>
The plaintiffs argue that this action was arbitrary, unlawful, and detrimental to patients who rely on compounded semaglutide for type 2 diabetes, obesity, and cardiovascular disease.
The <a target="_blank" href="https://www.503bs.org/_files/ugd/90544a_2f297f7c5f2a45fb89f64fe6a5dcb5c7.pdf" rel="noreferrer noopener">lawsuit</a> highlights that even the manufacturer of FDA-approved semaglutide acknowledged in its earnings release that supply issues and drug <a target="_blank" href="https://www.benzinga.com/25/02/43491991/novo-nordisk-records-more-than-double-wegovy-sales-in-q4-seeks-regulatory-approval-for-hybrid-weight-loss-drug-in-2026" rel="noreferrer noopener">shortages were ongoing</a>.
Despite this, the FDA proceeded with its decision without engaging in a formal notice-and-comment rulemaking process, which plaintiffs argue violates the Administrative Procedure Act (APA).
The APA requires federal agencies to provide public notice, solicit input from stakeholders, and offer reasoned explanations for regulatory actions.
In December, Novo Nordisk&nbsp;submitted a Citizen Petition to the FDA requesting the exclusion of liraglutide from the 503B Bulks List, a registry of substances that outsourcing facilities may <a target="_blank" href="https://www.benzinga.com/25/01/42811734/novo-nordisk-pushes-fda-to-exclude-compounding-for-its-early-generation-diabetes-drug" rel="noreferrer noopener">use in drug compounding</a>.
The petition argues that FDA-approved liraglutide-based products, Victoza, Saxenda, and Xultophy, meet patient needs without requiring additional compounded versions, which Novo Nordisk contends pose significant safety and efficacy risks.
Last year, the FDA determined that the Eli Lilly And Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) tirzepatide injection shortage had been resolved.
The compounding groups <a target="_blank" href="https://www.503bs.org/_files/ugd/90544a_956a40069f7c4b768199e187953cd15f.pdf" rel="noreferrer noopener">filed</a> a complaint alleging that removing the drug from the shortage list is based solely on the manufacturer's production capabilities.
In January, Eli Lilly filed a motion to intervene as a defendant in a case against the FDA brought by the Outsourcing Facilities Association and <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42783449/eli-lilly-joins-fda-lawsuit-over-compounded-obesity-drugs-seeks-swift-end-and-to-protect-its-interests" rel="noreferrer noopener">FarmaKeio Custom Compounding</a>.
Price Action: LLY stock is up 1.22% at $912.79 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43980584/united-parks-q4-earnings-miss-estimates-as-unusually-poor-weather-impacts-results" target="_blank" rel="noreferrer noopener">United Parks Q4 Earnings Miss Estimates As ‘Unusually Poor' Weather Impacts Results</a></li>
</ul>
Image via Shutterstock

Legal

Novo Nordisk's Ozempic And Wegovy No Longer on FDA Shortage List, Faces Lawsuit Over Decision

AMGN

VKTX

Drug Compounders Sue U.S. Drug Regulator Over Removal Of Novo Nordisk Diabetes, Weight Loss Drugs From Shortage List

President Donald Trump reportedly issued a stringent warning to pharmaceutical companies, advising them to repatriate their manufacturing to the U.S. or face the possibility of tariffs.
What Happened: During a confidential meeting, Trump alerted drug companies about the impending tariffs, urging them to hasten the transfer of their overseas production to the U.S., reported <a href="https://www.bloomberg.com/news/articles/2025-02-21/trump-told-drugmakers-to-move-production-to-us-or-face-tariffs">Bloomberg</a> on Friday.
On Thursday, the CEO of Eli Lilly &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) David Ricks, CEO of Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Robert Davis, CEO OF Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Albert Bourla, and Stephen Ubl, head of the industry&#8217;s largest lobbying group met Trump at the White House. The executives aimed to persuade Trump to back efforts to limit a law permitting the federal government to negotiate specific drug prices and to support measures targeting middlemen whom the industry holds responsible for increasing out-of-pocket costs.
As per the Bloomberg report, Trump did not assure to advocate with Congress to alleviate a drug pricing program established under former President Joe Biden&#8216;s tenure, a relief that the pharmaceutical sector has been seeking.
Medicare officials confirmed on Friday that the next phase of the drug pricing negotiation program&nbsp;is due and would include Novo Nordisk&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) blockbuster weight loss drugs, Ozempic and Wegovy. 
Meanwhile, Trump stated that Health and Human Services Secretary Robert F. Kennedy Jr. and his nominee for leading Medicare and Medicaid, Mehmet Oz, are working to reduce drug prices.
SEE ALSO: <a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43904842/dominos-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">Domino&#8217;s Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a>
Why It Matters: Last week, Trump proposed to <a href="https://www.benzinga.com/25/02/43805852/trump-shakes-global-trade-with-25-auto-chip-and-pharma-tariffs-announcement-asian-stocks-pare-their-five-day-rally">impose a 25% tariff </a>on pharmaceuticals imported to the U.S. This latest move by Trump is not surprising given his previous confrontations with the pharmaceutical industry. During his first term, he even accused them at one point of &#8220;getting away with murder&#8221; with their drug pricing. 
ING Bank estimates that the U.S. imported nearly 36% of the drugs in 2024 with Ireland, Germany, and Switzerland being the top importers. Meanwhile, data from the Atlantic Council shows that U.S. imports of Chinese drugs surged 485% between 2020-2022.&nbsp;Following Trump&#8217;s latest warning to drugmakers to shift production in the U.S., Chinese biotech shares have taken a hit during their Asian trading session today. Shares of WuXi Biologics (OTC:<a class="ticker" href="https://www.benzinga.com/stock/WXXWY#OTC">WXXWY</a>), WuXi AppTec (OTC:<a class="ticker" href="https://www.benzinga.com/stock/WUXAY#OTC">WUXAY</a>) and Pharmaron Beijing (OTC:<a class="ticker" href="https://www.benzinga.com/stock/PHBBF#OTC">PHBBF</a>) witnessed significant declines. 
That being said, ING asserted that Trump&#8217;s call for expanding U.S. pharmaceutical manufacturing is justified, as a report from the Biden administration had indicated that capacity restrictions were the cause of drug shortages. However, a 2022 report by Washington University&nbsp;revealed that the capacity expansion would take between two to three years. 
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/news/25/02/43901182/bernie-sanders-warns-if-elon-musk-can-fire-hundreds-of-thousands-of-federal-employees-imagine-what-hell-do-to-private-sector-workers">Bernie Sanders Warns: If Elon Musk Can Fire Hundreds Of Thousands Of Federal Employees, Imagine What He&#8217;ll Do To Private Sector Workers</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Politics

Markets

PHBBF

WUXAY

WXXWY

Trump Reportedly Warns Big Pharma: Move Manufacturing To US Or Face Tariffs

According to multiple media reports on Thursday, Pfizer&nbsp;Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) has terminated the global development and commercialization of its hemophilia B gene therapy, Beqvez.
In April 2024, the FDA approved Beqvez for moderate to severe hemophilia B in adult patients who currently use factor IX prophylaxis therapy or have current or historical life-threatening hemorrhage, or have repeated,&nbsp;serious spontaneous&nbsp;bleeding episodes, and do not have neutralizing antibodies to&nbsp;adeno-associated&nbsp;virus&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38468053/fda-green-lights-pfizers-gene-therapy-for-rare-bleeding-disorder-hemophilia" rel="noreferrer noopener">serotype Rh74var capsid</a>.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43569013/uniqure-csl-behrings-hemophilia-gene-therapy-shows-sustained-efficacy-and-safety-at-four-years" rel="noreferrer noopener">uniQure/ CSL Behring&#8217;s Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years</a>
In a statement to&nbsp;Nikkei Asia, Pfizer <a target="_blank" href="https://asia.nikkei.com/Business/Pharmaceuticals/Pfizer-halts-work-on-hemophilia-gene-therapy" rel="noreferrer noopener">said</a> the decision was due to "the limited interest patients and their doctors have demonstrated in hemophilia gene therapies.&#8221;
The U.S. drugmaker said it would focus on different treatment for the disorder, citing low interest.
In December 2024, Pfizer walked away&nbsp;from its hemophilia A co-development pact with Sangamo Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) giroctocogene fitelparvovec, an investigational gene <a target="_blank" href="https://www.benzinga.com/24/12/42740738/sangamo-therapeutics-stock-plunges-as-pfizer-terminates-hemophilia-gene-therapy-pact" rel="noreferrer noopener">therapy product candidate</a>.
According to a Reuters report, Pfizer will continue to invest resources in Hympavzi (marstacimab-hncq), which is approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients with hemophilia A or hemophilia B.
Hympavzi is the first and only anti-tissue factor pathway inhibitor (anti-TFPI) approved in the U.S. for hemophilia A or B and the first hemophilia medicine approved in the U.S. to be administered via a pre-filled,&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41310468/fda-approves-pfizers-second-hemophilia-drug-with-six-months" rel="noreferrer noopener">auto-injector pen</a>.
Earlier this month, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with hemophilia A <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43557877/novo-nordisk-eyes-2025-regulatory-filing-for-hemophilia-candidate-after-encouraging-pediatric-study-data" rel="noreferrer noopener">with and without inhibitors</a>.
Novo Nordisk expects Mim8 regulatory submission during 2025. Data from the ongoing phase 3 FRONTIER program will be disclosed at upcoming congresses and in publications in 2025 and 2026.
In September 2024, Pfizer voluntarily withdrew all lots of Oxbryta&nbsp;(voxelotor) for sickle cell disease (SCD) in all markets&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/b41035514/pfizer-voluntarily-withdraws-all-lots-of-sickle-cell-disease-treatment-oxbryta-voxelotor-from-worl" rel="noreferrer noopener">where it is approved</a>.
Pfizer's decision is based on the totality of clinical data indicating that the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41048780/pfizer-voluntarily-withdraws-sickle-cell-disease-treatment-oxbryta-from-global-market-due-to-pain" rel="noreferrer noopener">cell patient population</a>.
Price Action: PFE stock is up 0.87% at $26.13 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43885302/apple-expands-apple-tv-to-android-eyes-subscription-growth-and-ecosystem-expansion-analyst-says" target="_blank" rel="noreferrer noopener">Apple Expands Apple TV+ to Android, Eyes Subscription Growth and Ecosystem Expansion, Analyst Says</a></li>
</ul>

SGMO

Pfizer Discontinues Hemophilia Gene Therapy Beqvez As Interest Wanes

WIIM

Novo Nordisk shares are trading higher after the FDA announced that the injection shortage for the company's Ozemic and Wegovy injections is resolved.

DRIO

Hims & Hers Health, Inc. Class A Common Stock

HIMS

LFVN

RHHBY

TERN

VANI

FDA Says Novo Nordisk's Ozempic Injection .68 mg/1 ml, Injection 1.34 mg/1 ml, Injection 2.68 Mg/1 ml Available As Of Feb 21; Novo Nordisk's Wegovy, Injection, 1.7 mg/.75 ml , Wegovy, Injection, 2.4 mg/.75 ml Now Available; FDA Says Semaglutide Injection Shortage Is Resolved As Of Feb 21

Hims & Hers Health shares are trading lower after the company announced it acquired a U.S.-based peptide facility. Additionally, it was reported that the FDA said the semaglutide injection shortage is resolves as of Feb. 21.

Whales with a lot of money to spend have taken a noticeably bullish stance on Novo Nordisk.
Looking at options history for Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) we detected 12 trades.
If we consider the specifics of each trade, it is accurate to state that 58% of the investors opened trades with bullish expectations and 41% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $136,075 and 10, calls, for a total amount of $989,743.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $70.0 to $125.0 for Novo Nordisk during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Novo Nordisk's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Novo Nordisk's whale activity within a strike price range from $70.0 to $125.0 in the last 30 days. 
<h3>Novo Nordisk Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739992546_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$5.3</td>
<td>$5.0</td>
<td>$5.05</td>
<td>$110.00</td>
<td>$606.0K</td>
<td>1.9K</td>
<td>1.2K</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$18.0</td>
<td>$17.8</td>
<td>$18.0</td>
<td>$95.00</td>
<td>$106.2K</td>
<td>601</td>
<td>60</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$5.65</td>
<td>$5.55</td>
<td>$5.55</td>
<td>$85.00</td>
<td>$73.2K</td>
<td>2.1K</td>
<td>95</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$18.0</td>
<td>$17.8</td>
<td>$17.8</td>
<td>$75.00</td>
<td>$53.4K</td>
<td>199</td>
<td>2</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$14.95</td>
<td>$14.7</td>
<td>$14.85</td>
<td>$70.00</td>
<td>$46.0K</td>
<td>44</td>
<td>31</td>
</tr>
</tbody>
</table>

<h3>About Novo Nordisk</h3>
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Having examined the options trading patterns of Novo Nordisk, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Novo Nordisk Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 3,760,951, the NVO's price is up by 1.01%, now at $83.16. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 77 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Novo Nordisk options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity

Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) has outperformed the market over the past 10 years by 2.2% on an annualized basis producing an average annual return of 13.35%. Currently, Novo Nordisk has a market capitalization of $367.86 billion. 
Buying $1000 In NVO: If an investor had bought $1000 of NVO stock 10 years ago, it would be worth $3,489.99 today based on a price of $82.87 for NVO at the time of writing.
<h3>Novo Nordisk's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739979008_0_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth This Much Today

On Friday, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) filed an urgent request for a worldwide freezing order against KBP Biosciences Pte. Ltd. and Dr. Huang Zhenhua, KBP's founder, Executive Chairman and a 40% shareholder.
The case revolves around Novo Nordisk's claim that KBP misled it into buying the rights to Ocedurenone, a drug for hypertension and kidney disease.
Novo argues that KBP failed to disclose crucial data suggesting the drug was ineffective.
In October 2023, Novo Nordisk <a target="_blank" href="https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=166329" rel="noreferrer noopener">agreed</a> to acquire ocedurenone for up to $1.3 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43557877/novo-nordisk-eyes-2025-regulatory-filing-for-hemophilia-candidate-after-encouraging-pediatric-study-data" rel="noreferrer noopener">Novo Nordisk Eyes 2025 Regulatory Filing For Hemophilia Candidate After Encouraging Pediatric Study Data</a>
At that time, the company said Ocedurenone was being examined in the phase 3 trial CLARION-CKD in patients with uncontrolled hypertension and advanced chronic kidney disease.
In June 2024, Novo Nordisk <a target="_blank" href="https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=168529" rel="noreferrer noopener">announced</a> that the CLARION-CKD phase 3 trial failed to meet its primary endpoint. The Danish drug giant recognized an impairment loss of around 5.7 billion Danish kroner related to the intangible asset ocedurenone.
Tucked in its third-quarter earnings release, Novo Nordisk <a target="_blank" href="https://ml-eu.globenewswire.com/Resource/Download/11f24e9a-5374-4abf-afc1-a31bc257a98a" rel="noreferrer noopener">said</a> that following the stop of the ocedurenone CLARION-CKD phase 3 trial, based on the interim analysis in June, Novo Nordisk has analyzed detailed trial data and decided to terminate further development of ocedurenone.
Novo Nordisk is <a target="_blank" href="https://www.elitigation.sg/gd/sic/2025_SGHCI_3" rel="noreferrer noopener">seeking</a> this order as part of a planned arbitration in New York, where it intends to claim $830 million in damages, with $100 million already held in escrow.
The judge says, "KBP knowingly failed to disclose material information, including interim analyses of Phase 2 clinical trial results showing Ocedurenone's inefficacy, and information concerning quality and compliance issues at a single test site that produced anomalous positive results. Likewise, Dr Huang arguably knew and participated in these misrepresentations."
Price Action: NVO stock is up 0.60% at $82.83&nbsp;during the premarket session on last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/guidance/25/02/43810612/wrangler-lee-parent-kontoor-brands-snaps-up-helly-hansen-for-900m-details" target="_blank" rel="noreferrer noopener">Wrangler &amp; Lee Parent Kontoor Brands Snaps Up Helly Hansen For $900M: Details</a></li>
</ul>
Photo via Shutterstock

Novo Nordisk Sues Singapore-Based KBP Biosciences Over Alleged Data Misrepresentation In $1.3 Billion Hypertension Drug Deal, Seeks Damages

Novo Nordisk shares are trading higher. The stock may be moving after Sanofi announced FDA approval for Merilog, its first rapid-acting insular product for diabetes, which is biosimilar to Novo Nordisk's insulin products.

On Friday, the FDA approved Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) Merilog as a biosimilar to Novo Nordisk A/S&#8216; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Novolog (insulin aspart) for improving glycemic control in adults and pediatric patients with diabetes mellitus.
Merilog, a rapid-acting human insulin analog, is the first rapid-acting insulin biosimilar product approved by the FDA.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43692253/sanofi-johnson-johnson-partnered-vaccine-against-bacterial-sepsis-flunks-late-stage-study" rel="noreferrer noopener">Sanofi/Johnson &amp; Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study</a>
As a rapid-acting insulin, Merilog helps lower mealtime blood sugar spikes and improve blood sugar control in people with diabetes. The <a target="_blank" href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-rapid-acting-insulin-biosimilar-product-treatment-diabetes" rel="noreferrer noopener">approval </a>is for a 3 milliliter (mL) single-patient-use prefilled pen and a 10 milliliter (mL) multiple-dose vial.
Merilog is the third insulin biosimilar product the FDA has approved, joining the two long-acting insulin biosimilar products the agency approved in 2021.
A biosimilar is a &#8220;biological product that is highly similar to, and has no clinically meaningful differences from, a biological product already approved by the FDA (also called the reference product).&#8221; The FDA has approved 65 biosimilar products to date.
Like Novolog, Merilog should be administered within five to ten minutes before the start of a meal. Merilog is administered subcutaneously (under the skin) by injection into the stomach, buttocks, thighs, or upper arms. Dosing of Merilog should be individualized and adjusted based on the patient&#8217;s needs.
Merilog may cause serious side effects, including hypoglycemia (low blood sugar), severe allergic reactions, and hypokalemia (low potassium in blood). Other common side effects may include injection site reactions, itching, rash, lipodystrophy (skin thickening or pitting at the injection site), weight gain, and swelling of hands and feet.
In 2023, Sanofi jumped the bandwagon with the other two insulin U.S. giants to&nbsp;lower the price of its best-selling insulin product, Lantus <a target="_blank" href="https://www.benzinga.com/general/biotech/23/03/31394427/three-is-company-sanofi-follows-lilly-novo-nordisk-slashes-insulin-product-price-by-78" rel="noreferrer noopener">(insulin glargine), by 78%</a>.
Sanofi said it would cap a&nbsp;Lantus patient&#8217;s monthly out-of-pocket cost at $35 for all patients with commercial insurance.&nbsp;
Also, in 2023, Sanofi acquired&nbsp;Provention Bio for $25.00 per share in cash, representing an equity value of <a target="_blank" href="https://www.benzinga.com/general/biotech/23/03/31318877/provention-bios-2-9b-acquisition-a-strategic-fit-for-sanofi" rel="noreferrer noopener">approximately $2.9 billion</a>.
The transaction adds a type 1 diabetes therapy to Sanofi&#8217;s core asset portfolio in General Medicines and further drives its strategic shift toward products with a differentiated profile.&nbsp;
In November, Doctors Without Borders/Médecins Sans Frontières highlighted that&nbsp;Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Novo Nordisk, and Sanofi, which dominate the global insulin market, have the power to set high&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41940958/humanitarian-organization-criticizes-eli-lilly-novo-nordisk-and-sanofi-of-having-double-standards-for-high-insulin-price" rel="noreferrer noopener">prices that restrict access</a>.
According to MSF, data published in&nbsp;JAMA Network Open&nbsp;shows that insulin pens could be produced for as little as $0.94 per unit and remain profitable, yet current prices far exceed this figure.
Price Action: SNY stock is down 0.59% at $54.18 during the premarket session on last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/02/43744606/analyst-cautiously-optimistic-on-dexcom-as-competitive-pressures-loom" target="_blank" rel="noreferrer noopener">Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom</a></li>
</ul>
Image by HJBC via Shutterstock

FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes

U.S. FDA Approves Sanofi-Aventis U.S' Merilog & Merilog Solostar, Biosimilars To Novo Nordisk's Novolog

<a href="https://www.sec.gov/Archives/edgar/data/1167483/000091957425001475/xslForm13F_X02/infotable.xml">https://www.sec.gov/Archives/edgar/data/1167483/000091957425001475/xslForm13F_X02/infotable.xml</a>

AMAT

CPNG

RDDT

SPOT

UBER

Tiger Global Management's Latest 13F Filing Shows Increased Positions In Eli Lilly By 1.31M Shares, Reddit By 2.03M Shares, Coupang By 8.12M Shares, Sherwin-Williams By 1.00M Shares, Spotify By 1.26M Shares; Decreased Holdings In UnitedHealth By 438.8K Shares, Nu Holdings By 8.88M Shares, Uber Technologies By 2.60M Shares, Applied Materials By 895.2K Shares, Novo Nordisk By 1.27M Shares

Investors with a lot of money to spend have taken a bullish stance on Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with NVO, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 24 uncommon options trades for Novo Nordisk.
This isn't normal.
The overall sentiment of these big-money traders is split between 58% bullish and 33%, bearish.
Out of all of the special options we uncovered, 16 are puts, for a total amount of $1,137,714, and 8 are calls, for a total amount of $752,452.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $50.0 to $145.0 for Novo Nordisk over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Novo Nordisk's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Novo Nordisk's whale trades within a strike price range from $50.0 to $145.0 in the last 30 days. 
<h3>Novo Nordisk Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739552433_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$6.3</td>
<td>$6.0</td>
<td>$6.3</td>
<td>$85.00</td>
<td>$362.9K</td>
<td align="right">12</td>
<td align="right">641</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$67.4</td>
<td>$66.15</td>
<td>$66.15</td>
<td>$145.00</td>
<td>$330.7K</td>
<td align="right">4</td>
<td align="right">10</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$4.3</td>
<td>$4.1</td>
<td>$4.2</td>
<td>$70.00</td>
<td>$210.0K</td>
<td align="right">0</td>
<td align="right">501</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$6.35</td>
<td>$6.25</td>
<td>$6.3</td>
<td>$85.00</td>
<td>$195.3K</td>
<td align="right">12</td>
<td align="right">951</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/14/25</td>
<td>$13.05</td>
<td>$12.0</td>
<td>$12.15</td>
<td>$91.00</td>
<td>$66.8K</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h3>About Novo Nordisk</h3>
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
In light of the recent options history for Novo Nordisk, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Novo Nordisk's Current Market Status</h3>
<ul>
<li>With a trading volume of 3,949,255, the price of NVO is down by -0.2%, reaching $78.67.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 82 days from now.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Novo Nordisk options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

A Closer Look at Novo Nordisk's Options Market Dynamics

Novo Nordisk's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) short percent of float has risen 65.38% since its last report. The company recently reported that it has 13.57 million shares sold short, which is 0.43% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.3 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Novo Nordisk Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739538919_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Novo Nordisk has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Novo Nordisk's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Novo Nordisk's peer group average for short interest as a percentage of float is 4.08%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Novo Nordisk?

On Wednesday, Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) reported a fourth-quarter EPS loss of 64 cents, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus loss of 1.07 euros</a>.
Total revenue for the fourth quarter of 2024 was 173.9 million euros, beating the consensus of 111.178 million euros compared to 137.7 million <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43674382/ascendis-pharma-reports-fourth-quarter-and-full-year-2024-financial-results" rel="noreferrer noopener">euros reported a year ago</a>.
The increase was primarily due to Novo Nordisk A/S&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) $100 million upfront fee and the EU launch of Yorvipath.
TransCon hGH (lonapegsomatropin, marketed as Skytrofa) sales reached 58.5 million euros.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41723496/wegovy-manufacturer-inks-multi-million-deal-for-monthly-obesity-drug" rel="noreferrer noopener">Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug</a>
TransCon PTH (palopegteriparatide, marketed as Yorvipath) revenue for the fourth quarter of 2024 totaled €13.6 million.
The company reported a strong start to the U.S. Yorvipath launch, with 908 prescriptions as of February 7, 2025, and 539 unique prescribing health care providers.
As of December 31, 2024, cash and cash equivalents totaled 559.5 million euros. Including the $100 million upfront payment, cash at the end of 2024 would have totaled 655 million euros.
Concurrently, Ascendis Pharma's board authorized the repurchase of up <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43674574/ascendis-pharma-as-announces-share-repurchase-program-net-settlement-of-certain-rsus" rel="noreferrer noopener">to $18.25 million shares</a>.
Goldman Sachs analyst writes that Yorvipath has only been available in the U.S. for a few months, but early prescription trends have been strong and widespread. However, insurance coverage and reimbursement challenges may slow revenue growth in the short term.
Looking ahead, analyst Paul Choi writes investors will likely focus on the company's progress toward achieving breakeven cash flow and key milestones, including:
<ul>
<li>The pace of Yorvipath's rollout in the U.S. and EU</li>
<li>Data from the COACH study on achondroplasia, expected in Q2 2025</li>
<li>Regulatory discussions on Transcon CNP</li>
<li>Competitive updates from BioMarin Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) in achondroplasia and AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) in hypoparathyroidism.</li>
</ul>
With Yorvipath showing potential for a strong launch in 2025, Goldman Sachs maintains the Buy rating and raises the price target <a target="_blank" href="https://www.benzinga.com/quote/CVS/analyst-ratings" rel="noreferrer noopener">to $225 from $200</a>.
Price Action: ASND stock is up 15.8% at $146.08 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/02/43697905/zoetis-drops-as-2025-guidance-falls-short-of-estimates" target="_blank" rel="noreferrer noopener">Zoetis Drops As 2025 Guidance Falls Short Of Estimates</a></li>
</ul>

Earnings

Guidance

Price Target

ASND

BMRN

Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?

Financial giants have made a conspicuous bearish move on Novo Nordisk. Our analysis of options history for Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) revealed 18 unusual trades.
Delving into the details, we found 33% of traders were bullish, while 55% showed bearish tendencies. Out of all the trades we spotted, 10 were puts, with a value of $701,147, and 8 were calls, valued at $291,676.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $70.0 to $150.0 for Novo Nordisk over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Novo Nordisk's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Novo Nordisk's whale trades within a strike price range from $70.0 to $150.0 in the last 30 days. 
<h3>Novo Nordisk 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738949430_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/07/25</td>
<td>$0.6</td>
<td>$0.51</td>
<td>$0.51</td>
<td>$79.00</td>
<td>$207.4K</td>
<td>55</td>
<td>5.2K</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$2.68</td>
<td>$2.39</td>
<td>$2.44</td>
<td>$70.00</td>
<td>$146.4K</td>
<td>2.8K</td>
<td>1</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$2.76</td>
<td>$2.57</td>
<td>$2.76</td>
<td>$70.00</td>
<td>$110.4K</td>
<td>2.8K</td>
<td>1.6K</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/07/25</td>
<td>$3.65</td>
<td>$3.6</td>
<td>$3.65</td>
<td>$88.00</td>
<td>$54.3K</td>
<td>215</td>
<td>171</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$3.15</td>
<td>$3.05</td>
<td>$3.1</td>
<td>$89.00</td>
<td>$50.5K</td>
<td>67</td>
<td>0</td>
</tr>
</tbody>
</table>

<h3>About Novo Nordisk</h3>
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
<h3>Present Market Standing of Novo Nordisk</h3>
<ul>
<li>With a trading volume of 4,896,136, the price of NVO is up by 1.72%, reaching $88.67.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 83 days from now.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Novo Nordisk, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

What the Options Market Tells Us About Novo Nordisk

Press Releases

Novo Nordisk A/S Investors: Please contact the Portnoy Law Firm to recover your losses; March 25, 2025 Deadline to file Lead Plaintiff Motion

Novo Nordisk (NVO) Faces Securities Class Action After Weight Loss Therapy Trial Data Disappoints, Analyst Questions Trial's Design – Hagens Berman

March 25, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against  NVO

Novo Nordisk (NVO) Hit with Investor Lawsuit Over CagriSema Obesity Drug - Hagens Berman

NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit

ROSEN, LEADING INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVO

Shareholders that lost money on Novo Nordisk A/S(NVO) should contact The Gross Law Firm about pending Class Action - NVO

Novo Nordisk A/S Sued for Securities Law Violations - Contact The Gross Law Firm Before March 25, 2025 to Discuss Your Rights – NVO

INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Lawsuit Against Novo Nordisk A/S - NVO

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against TELUS International, Novo Nordisk, Micron, and ModivCare and Encourages Investors to Contact the Firm

MODV

TIXT

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

BMO Capital

Cantor Fitzgerald

Argus Research

Morgan Stanley

Screenshot 2024-11-20 at 6.30.30 PM

BRTX

BioRestorative Ends Q3 In &#39;Strong&#39; Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Screenshot 2024-09-10 at 4.29.40 PM

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?

Screenshot 2024-08-22 at 5.32.58 PM

RDHL

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Screenshot 2024-06-18 at 1.15.14 AM

BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies

Screenshot 2024-05-16 at 5.52.00 PM

ELAB

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Screenshot 2024-02-22 at 11.51.01 PM

BTTX

Better Therapeutics Follows Up Wins Including FDA Authorization For AspyreRx In 2023 With Securing FDA Breakthrough Device Designation Targeting Advanced Liver Disease

Comments

Novo Nordisk

Noticias

Últimas noticias sobre Novo Nordisk (NYSE:NVO) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL